Unnamed: 0,title,date,stock,sentiment
652520.0,Idera Pharmaceuticals Files For Resale Of 6.1M Shares Of Common Stock By Selling Shareholders,2020-06-02 08:34:00-04:00,IDRA,positive
652521.0,Idera Pharmaceuticals Announces Preliminary Data From And Planned Continuation Of ILLUMINATE-206 Trial For Treatment Of Micro-Satellite Stable Colorectal Cancer,2020-06-02 08:15:00-04:00,IDRA,negative
652522.0,Idera Pharmaceuticals Q1 EPS $0.220 Up From $(0.400) YoY,2020-04-30 16:39:00-04:00,IDRA,neutral
652523.0,"The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight",2020-04-26 16:37:00-04:00,IDRA,negative
652524.0,Idera Pharmaceuticals Announces Tilsotolimod Program Updates To Be Presented At AACR Virtual Annual Meeting 2020,2020-04-23 07:35:00-04:00,IDRA,neutral
652525.0,"Idera Pharma Reports Final Clinical Safety, Efficacy Data From Illuminate-204 Trial In Advanced Melanoma: Overall Response Rate 22%, Disease Control Rate 71%",2020-04-21 07:31:00-04:00,IDRA,positive
652526.0,86 Biggest Movers From Yesterday,2020-04-09 05:43:00-04:00,IDRA,negative
652527.0,65 Stocks Moving In Wednesday's Mid-Day Session,2020-04-08 12:35:00-04:00,IDRA,neutral
652528.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,IDRA,neutral
652529.0,30 Stocks Moving in Wednesday's Pre-Market Session,2020-04-08 07:24:00-04:00,IDRA,neutral
652530.0,6 Stocks Moving In Tuesday's After-Hours Session,2020-04-07 16:41:00-04:00,IDRA,neutral
652531.0,Idera Pharmaceuticals shares are trading higher after the company announced a $20.7 million private placement.,2020-04-07 16:10:00-04:00,IDRA,positive
652532.0,Idera Pharma Reports $20.7M Private Placement,2020-04-07 16:08:00-04:00,IDRA,neutral
652533.0,Idera Pharmaceuticals Announces Private Placement Of Up To $20.7M,2020-04-07 16:05:00-04:00,IDRA,neutral
652534.0,"The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO",2020-03-12 07:37:00-04:00,IDRA,negative
652535.0,Idera Pharmaceuticals Q4 EPS $(1.76) Down From $(0.45) YoY,2020-03-12 07:36:00-04:00,IDRA,neutral
652536.0,Stocks That Hit 52-Week Lows On Wednesday,2020-03-11 11:41:00-04:00,IDRA,negative
652537.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,IDRA,negative
652538.0,Idera Pharma Reports Completion Of Enrollment In ILLUMINATE-301 Trial,2020-03-05 07:12:00-05:00,IDRA,neutral
652539.0,98 Biotechnology Stocks Moving In Wednesday's Session,2020-01-22 13:33:00-05:00,IDRA,neutral
652540.0,82 Biggest Movers From Yesterday,2020-01-22 04:18:00-05:00,IDRA,neutral
652541.0,55 Stocks Moving In Tuesday's Mid-Day Session,2020-01-21 12:14:00-05:00,IDRA,neutral
652542.0,Idera Pharmaceuticals Provides 2020 Update,2020-01-14 07:10:00-05:00,IDRA,neutral
652543.0,"Idera Pharmaceuticals On Dec. 23, Co Entered Into A Securities Purchase Agreement",2019-12-23 16:04:00-05:00,IDRA,positive
652544.0,Idera Pharmaceuticals Announces Private Placement Up To $97.7M,2019-12-23 09:16:00-05:00,IDRA,neutral
652545.0,"The Daily Biotech Pulse: Roche Gets US Antitrust Clearance For Spark Purchase, An Orphan Drug Designation For Prevail, Dynavax Names CEO",2019-12-17 07:56:00-05:00,IDRA,positive
652546.0,"The Daily Biotech Pulse: Second Time's The Charm For Sarepta, Pfizer's Xeljanz Snags Third Approval, NewLink Genetics Rejects Competing Offer",2019-12-13 08:10:00-05:00,IDRA,positive
652547.0,"The Daily Biotech Pulse: European Nod For Amgen, miRagen Overhauls Clinical Pipeline, Tonix Snags Patent Win",2019-12-12 07:38:00-05:00,IDRA,positive
652548.0,"The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint",2019-12-11 07:21:00-05:00,IDRA,negative
652549.0,Stocks That Hit 52-Week Lows On Tuesday,2019-12-10 14:29:00-05:00,IDRA,negative
652550.0,Stocks That Hit 52-Week Lows On Friday,2019-11-29 11:04:00-05:00,IDRA,negative
652551.0,"The Daily Biotech Pulse: Roche-Spark Deal Extended Again, Zymeworks' Positive Readout, Enanta Misses Earnings Estimate",2019-11-22 08:18:00-05:00,IDRA,positive
652552.0,Stocks That Hit 52-Week Lows On Thursday,2019-11-21 11:09:00-05:00,IDRA,negative
652553.0,"The Daily Biotech Pulse: Patent Win For Cellectis, Hepion Proves Efficacy In Animal Model, Job Cuts At Neon",2019-11-21 07:22:00-05:00,IDRA,positive
652554.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,IDRA,neutral
652555.0,Idera Pharmaceuticals Q3 EPS $(0.39) Beats $(0.46) Estimate,2019-11-06 16:21:00-05:00,IDRA,neutral
652556.0,Idera Pharmaceuticals Announces New US Patent For Tilsotolimod Through September 2037,2019-10-21 07:08:00-04:00,IDRA,neutral
652557.0,58 Biggest Movers From Yesterday,2019-10-01 05:56:00-04:00,IDRA,neutral
652558.0,84 Biggest Movers From Yesterday,2019-09-10 05:01:00-04:00,IDRA,neutral
652559.0,44 Stocks Moving In Monday's Mid-Day Session,2019-09-09 12:21:00-04:00,IDRA,neutral
652560.0,"JMP Securities Assumes Idera Pharmaceuticals at Market Outperform, Announces $7 Price Target",2019-09-05 08:10:00-04:00,IDRA,positive
652561.0,60 Biggest Movers From Yesterday,2019-09-05 05:20:00-04:00,IDRA,neutral
652562.0,46 Stocks Moving In Wednesday's Mid-Day Session,2019-09-04 12:27:00-04:00,IDRA,neutral
652563.0,Idera Pharmaceuticals shares are trading higher after the company announced it entered into an immuno-oncology research collaboration with AbbVie.,2019-09-04 08:31:00-04:00,IDRA,positive
652564.0,10 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-04 08:13:00-04:00,IDRA,neutral
652565.0,Idera Pharmaceuticals Announces Immuno-Oncology Clinical Research Collaboration With AbbVie,2019-09-04 07:03:00-04:00,IDRA,neutral
652566.0,"The Daily Biotech Pulse: Roche Snags Double Nod For Personalized Cancer Drug, Bellicum Offering, Nabriva Braces For Contepo Resubmission",2019-08-16 07:33:00-04:00,IDRA,negative
652567.0,"Idera Pharmaceuticals Q2 EPS $(0.39) Beats $(0.42) Estimate, Sales $1.448M Up From $163K YoY",2019-08-08 09:05:00-04:00,IDRA,neutral
652568.0,Idera Pharma Names John Kirby CFO,2019-07-23 07:39:00-04:00,IDRA,neutral
652569.0,58 Biggest Movers From Yesterday,2019-05-15 05:09:00-04:00,IDRA,neutral
652570.0,72 Biggest Movers From Yesterday,2019-05-08 06:17:00-04:00,IDRA,neutral
652571.0,44 Biggest Movers From Yesterday,2019-05-07 05:49:00-04:00,IDRA,neutral
652572.0,80 Biggest Movers From Friday,2019-05-06 05:54:00-04:00,IDRA,neutral
652573.0,58 Stocks Moving In Friday's Mid-Day Session,2019-05-03 14:25:00-04:00,IDRA,neutral
652574.0,"Idera Pharmaceuticals Q4 EPS $(0.45) Beats $(0.51) Estimate, Sales $99K Beat $40K Estimate",2019-05-02 18:20:00-04:00,IDRA,neutral
652575.0,42 Biggest Movers From Yesterday,2019-04-30 07:05:00-04:00,IDRA,neutral
652576.0,54 Biggest Movers From Yesterday,2019-04-03 05:42:00-04:00,IDRA,neutral
652577.0,51 Stocks Moving In Tuesday's Mid-Day Session,2019-04-02 12:27:00-04:00,IDRA,neutral
652578.0,Idera Pharmaceuticals Highlights Presentation Of ILLUMINATE-101 Data Demonstrating Tilsotolimod Activates Innate and Adaptive Immunity as Monotherapy in Patients with Refractory Solid Tumors At AACR 2019 Annual Meeting,2019-04-02 07:16:00-04:00,IDRA,positive
652579.0,Shares of the overall market are trading lower after the U.S. Treasury yield curve inverted for the first time since 2007.,2019-03-22 12:58:00-04:00,IDRA,positive
652580.0,7 Biggest Price Target Changes For Thursday,2019-03-07 09:57:00-05:00,IDRA,neutral
652581.0,"Daily Biotech Pulse: Allergan's Depression Drug Flunks Late-Stage Trial, Apellis Offering, ShockWave Medical IPO",2019-03-07 07:48:00-05:00,IDRA,negative
652582.0,Idera Pharmaceuticals Files Prospectus Supplement Related To Issuance And Sale Of Up To $35M Of Shares Of Common Stock,2019-03-06 16:41:00-05:00,IDRA,positive
652583.0,"Idera Pharmaceuticals Q4 EPS $(0.45) Beats $(0.51) Estimate, Sales $99K Beat $40K Estimate",2019-03-06 16:31:00-05:00,IDRA,neutral
652584.0,Idera Pharmaceuticals Completes Enrollment In ILLUMINATE-204 Trial Of The Combination Of Tilsotolimod And Ipilimumab For Unresectable Or Metastatic Melanoma Following Failure Of PD-1 Inhibitor Treatment,2019-02-27 07:10:00-05:00,IDRA,negative
652585.0,65 Biggest Movers From Yesterday,2019-02-22 05:02:00-05:00,IDRA,neutral
652586.0,42 Stocks Moving In Wednesday's Mid-Day Session,2019-02-13 12:25:00-05:00,IDRA,neutral
652587.0,35 Stocks Moving In Wednesday's Pre-Market Session,2019-02-13 08:47:00-05:00,IDRA,neutral
652588.0,"Stocks Which Set New 52-Week Low Yesterday, Jan. 24, 2019",2019-01-24 10:05:00-05:00,IDRA,negative
652589.0,"The Daily Biotech Pulse: Partial Clinical Hold On Advaxis Cervical Cancer Drug, Ohr's Reverse Split, Ironwood Starts Phase 1 Trial",2019-01-24 07:45:00-05:00,IDRA,negative
652590.0,54 Biggest Movers From Yesterday,2019-01-24 05:04:00-05:00,IDRA,neutral
652591.0,44 Biggest Movers From Friday,2019-01-14 04:46:00-05:00,IDRA,neutral
652592.0,58 Biggest Movers From Friday,2019-01-07 04:17:00-05:00,IDRA,neutral
652593.0,58 Biggest Movers From Yesterday,2019-01-04 05:35:00-05:00,IDRA,neutral
652594.0,66 Biggest Movers From Yesterday,2019-01-03 05:00:00-05:00,IDRA,neutral
652595.0,"Stocks Which Set New 52-Week Low Today, Wed., Jan. 2, 2019",2019-01-02 13:08:00-05:00,IDRA,negative
652596.0,20 Stocks Moving In Thursday's Pre-Market Session,2018-12-27 08:05:00-05:00,IDRA,neutral
652597.0,58 Biggest Movers From Yesterday,2018-12-20 05:01:00-05:00,IDRA,neutral
652598.0,"The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas",2018-12-19 07:46:00-05:00,IDRA,positive
652599.0,45 Biggest Movers From Yesterday,2018-12-19 05:01:00-05:00,IDRA,neutral
652600.0,"The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan",2018-12-18 08:00:00-05:00,IDRA,positive
652601.0,"Stocks Which Set New 52-Week Low Last Trading Session, Fri., Dec. 14, 2018",2018-12-17 11:48:00-05:00,IDRA,negative
652602.0,41 Biggest Movers From Friday,2018-12-17 05:35:00-05:00,IDRA,neutral
652603.0,Mid-Afternoon Market Update: Dow Down 450 Points; Crude Oil Falls 2.5%,2018-12-14 14:31:00-05:00,IDRA,negative
652604.0,26 Stocks Moving In Friday's Mid-Day Session,2018-12-14 12:21:00-05:00,IDRA,neutral
652605.0,Mid-Day Market Update: Dow Falls 250 Points; Civitas Solutions Rises After Q4 Results,2018-12-14 12:07:00-05:00,IDRA,positive
652606.0,Mid-Morning Market Update: Markets Open Lower; LVMH To Buy Belmond For $25/Share,2018-12-14 10:16:00-05:00,IDRA,negative
652607.0,20 Stocks Moving In Friday's Pre-Market Session,2018-12-14 08:11:00-05:00,IDRA,neutral
652608.0,"Idera Pharma Highlights Presentation Of Safety, Efficacy Update From ILLUMINATE-204 Trial Of Tilsotolimod, Ipilimumab Combo",2018-12-14 07:02:00-05:00,IDRA,positive
652609.0,"Idera Pharmaceuticals To Provide ILLUMINATE-204 Clinical Data Update On Friday, December 14, 2018",2018-12-12 16:04:00-05:00,IDRA,neutral
652610.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings",2018-12-08 10:02:00-05:00,IDRA,neutral
652611.0,88 Biggest Movers From Yesterday,2018-11-08 04:54:00-05:00,IDRA,neutral
652612.0,70 Stocks Moving In Wednesday's Mid-Day Session,2018-11-07 12:52:00-05:00,IDRA,neutral
652613.0,Mid-Day Market Update: Crude Oil Down 1.3%; SendGrid Shares Spike Higher,2018-11-07 12:08:00-05:00,IDRA,negative
652614.0,"Idera Pharmaceuticals, Inc. Q3 EPS $(0.43) Beats $(0.58) Estimate, Sales $145K Miss $2.46M Estimate",2018-11-06 16:50:00-05:00,IDRA,negative
652615.0,58 Biggest Movers From Friday,2018-10-22 05:11:00-04:00,IDRA,neutral
652616.0,Idera Pharmaceuticals Presents Data from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment at ESMO 2018,2018-10-19 06:04:00-04:00,IDRA,negative
652617.0,51 Biggest Movers From Yesterday,2018-09-25 04:53:00-04:00,IDRA,neutral
652618.0,42 Stocks Moving In Monday's Mid-Day Session,2018-09-24 12:39:00-04:00,IDRA,neutral
652619.0,"Benzinga's Top Upgrades, Downgrades For September 24, 2018",2018-09-24 09:17:00-04:00,IDRA,positive
652620.0,"Barclays Initiates Coverage On Idera Pharmaceuticals with Overweight Rating, Announces $14 Price Target",2018-09-24 08:34:00-04:00,IDRA,negative
652621.0,48 Biggest Movers From Yesterday,2018-09-13 05:01:00-04:00,IDRA,neutral
652622.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-09-12 12:28:00-04:00,IDRA,neutral
652623.0,"Idera Pharmaceuticals CFO Louis J. Arcudi III Is Leaving The Co.,",2018-09-11 07:02:00-04:00,IDRA,neutral
652624.0,28 Stocks Moving In Monday's Mid-Day Session,2018-08-20 12:35:00-04:00,IDRA,neutral
652625.0,58 Biggest Movers From Yesterday,2018-08-15 05:02:00-04:00,IDRA,neutral
652626.0,55 Biggest Movers From Yesterday,2018-08-14 04:50:00-04:00,IDRA,neutral
652627.0,Idera Pharmaceuticals shares are trading up 20.4%; Not seeing any news or catalyst to justify price action.,2018-08-13 13:53:00-04:00,IDRA,positive
652628.0,61 Biggest Movers From Friday,2018-08-13 06:43:00-04:00,IDRA,neutral
652629.0,60 Stocks Moving In Friday's Mid-Day Session,2018-08-10 13:27:00-04:00,IDRA,neutral
652630.0,77 Biggest Movers From Yesterday,2018-08-10 04:01:00-04:00,IDRA,neutral
652631.0,"Idera Pharmaceuticals Q2 EPS $(0.59) Misses $(0.10) Estimate, Sales $163K Beat $90K Estimate",2018-08-02 16:32:00-04:00,IDRA,negative
652632.0,"Stocks Which Set New 52-Week Low Yesterday, July 31",2018-08-01 12:16:00-04:00,IDRA,negative
652633.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,IDRA,negative
652634.0,65 Biggest Movers From Yesterday,2018-08-01 04:36:00-04:00,IDRA,neutral
652635.0,52 Stocks Moving In Tuesday's Mid-Day Session,2018-07-31 12:38:00-04:00,IDRA,neutral
652636.0,"Stocks Which Set New 52-Week Low Yesterday, July 30th",2018-07-31 09:25:00-04:00,IDRA,negative
652637.0,"Idera Pharmaceuticals Begins Trading On Split-Adjusted Basis Following 1-For-8 Reverse Stock Split; Some Platforms May Indicate Shares Trading Up 691%, Ignore",2018-07-30 12:08:00-04:00,IDRA,negative
652638.0,"Idera Pharmaceuticals Announces One-for-Eight Reverse Stock Split; Trading On Split-Adjusted Basis To Occur On July 30, 2018",2018-07-27 12:00:00-04:00,IDRA,neutral
652639.0,"Benzinga's Daily Biotech Pulse: Bellicum CFO Resigns, Roche's Trial Meets Endpoints, Avid Bioservices Turns To Black In Q4",2018-07-17 08:37:00-04:00,IDRA,neutral
652640.0,"Idera Pharma Ended Q1 With $107.5M Cash, Expected to Fund Operations Through Q3 2019; Announces Agreement With Bristol-Myers to Fund Ipilimumab for the Illuminate-301 Trial",2018-07-16 07:03:00-04:00,IDRA,positive
652641.0,"Benzinga's Daily Biotech Pulse: AbbVie Files sNDA For Leukemia Drug, AcelRx Offering, Aurinia Starts Mid-Stage Trial",2018-07-12 08:37:00-04:00,IDRA,neutral
652642.0,"Benzinga's Daily Biotech Pulse: Pfizer To Defer Price Hikes, Idera-BioCryst Merger Falls Through, ArQule To Offer Shares",2018-07-11 08:15:00-04:00,IDRA,neutral
652643.0,"Idera Pharma Shares Resume, Move Lower, Down 16%; BioCryst Shares Resume, Indicated Up 6.8%, Not Yet Seeing Updated Last Price",2018-07-10 16:30:00-04:00,IDRA,positive
652644.0,BioCryst Pharmaceuticals Announces Termination Of Merger Agreement with Idera Pharmaceuticals,2018-07-10 16:01:00-04:00,IDRA,positive
652645.0,"Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut",2018-06-28 08:26:00-04:00,IDRA,positive
652646.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,IDRA,positive
652647.0,"BioCryst Pharmaceuticals Board Receives Letter From Great Point Partners Opposing Proposed Merger With Idera Pharmaceuticals, Inc.",2018-06-20 16:23:00-04:00,IDRA,positive
652648.0,42 Biggest Movers From Yesterday,2018-06-13 05:31:00-04:00,IDRA,neutral
652649.0,41 Stocks Moving In Tuesday's Mid-Day Session,2018-06-12 12:29:00-04:00,IDRA,neutral
652650.0,Idera Pharmaceuticals Shares Down 8.8% After Co. Earlier Reported Its Phase 2 Trial Of IMO-8400 In Dermatomyositis Did Not Meet Primary Endpoint,2018-06-12 11:45:00-04:00,IDRA,positive
652651.0,Idera Pharma Reports Results From Phase 2 Trial Of IMO-8400 In Dermatomyositis: Did Not Meet Primary Endpoint,2018-06-12 07:33:00-04:00,IDRA,neutral
652652.0,Idera Pharmaceuticals ILLUMINATE-204 Trial Showed 38% Overall Response Rate In 21 Patients Including 2 Complete Responses Along WIth A Deisease Control Rate Of 71% (15 of 21 Patients),2018-06-04 07:32:00-04:00,IDRA,neutral
652653.0,The Week Ahead In Biotech: ASCO Presentations Dominate The Headlines,2018-06-03 19:27:00-04:00,IDRA,negative
652654.0,"Idera Pharmaceuticals Q1 EPS $(0.10) Misses $(0.09) Estimate, Sales $255K Beat $60K Estimate",2018-05-09 07:15:00-04:00,IDRA,negative
652655.0,Idera Pharma Reports Entered Clinical Development Support Deal With Pillar Partners Foundation For Expansion Of Clinical Research On IMO-2125 Beyond PD-1 Refractory Melanoma,2018-04-16 07:07:00-04:00,IDRA,positive
652656.0,RA Capital Mgmt. Issues Release Highlighting Opposition To BioCryst Pharma's Proposed Merger With Idera Pharma,2018-04-02 14:59:00-04:00,IDRA,neutral
652657.0,"Idera Pharma Reports Q4 EPS $(0.08) vs $(0.09) Est., Alliance Sales $173K vs $110K Est.",2018-03-07 07:33:00-05:00,IDRA,neutral
652658.0,Baker Bros Increases Stake in Idera Pharmaceuticals to 18% -13D/A,2018-03-06 17:10:00-05:00,IDRA,neutral
652659.0,Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma,2018-03-01 07:14:00-05:00,IDRA,neutral
652660.0,Biocryst Releases Investor Presentation on Proposed Merger with Idera,2018-02-22 06:12:00-05:00,IDRA,neutral
652661.0,UPDATE: BioCryst Pharma Shares Volatile But Largely Unaffected Over Last Min.; Great Point Partners Issues Release Highlighting Opposition To Deal With Idera Pharma,2018-02-16 13:23:00-05:00,IDRA,positive
652662.0,Pharma M&A Picks Up Momentum,2018-01-23 13:56:00-05:00,IDRA,neutral
652663.0,38 Biggest Movers From Yesterday,2018-01-23 04:55:00-05:00,IDRA,neutral
652664.0,Mid-Afternoon Market Update: Bioverativ Climbs Following $105/Share Offer From Sanofi; Recon Technology Shares Drop,2018-01-22 14:33:00-05:00,IDRA,neutral
652665.0,32 Stocks Moving In Monday's Mid-Day Session,2018-01-22 12:46:00-05:00,IDRA,neutral
652666.0,Mid-Day Market Update: Juno Therapeutics Surges On Acquisition News; Sanmina Shares Plummet,2018-01-22 12:02:00-05:00,IDRA,positive
652667.0,"BioCryst Shares to be Exchanged for 0.50 Share of the New Company, Idera Shares to be Exchanged For 0.20 Shares of the New Company",2018-01-22 08:32:00-05:00,IDRA,positive
652668.0,BioCryst Pharma and Idera Pharma to Merge,2018-01-22 08:31:00-05:00,IDRA,neutral
652669.0,"Idera Pharma Halted, News Pending",2018-01-22 08:26:00-05:00,IDRA,neutral
652670.0,Form 4 Filing Shows 10% Idera Pharmaceuticals Owner Pillar Invest Corporation Sold 200K Shares AT $Avg. Prices $2.40-$2.405,2018-01-19 16:56:00-05:00,IDRA,positive
652671.0,Idera Pharma Offers Update On Clinical Development Programs,2018-01-05 07:04:00-05:00,IDRA,neutral
652672.0,Idera Pharma Sees Current Cash Position Capable Of Funding Operations Into Q2'19,2018-01-05 07:04:00-05:00,IDRA,positive
652673.0,"Idera Pharma Shareholders Voted To Approve Reverse Stock Split Of Not Less Than 1-for-4, Not More Than 1-for-8",2018-01-05 07:04:00-05:00,IDRA,neutral
652674.0,33 Stocks Moving In Wednesday's Mid-Day Session,2017-11-29 12:28:00-05:00,IDRA,neutral
652675.0,35 Stocks Moving In Wednesday's Pre-Market Session,2017-11-29 08:04:00-05:00,IDRA,neutral
652676.0,Idera Pharma is Granted FDA Fast Track Designation for IMO-2125,2017-11-29 07:34:00-05:00,IDRA,positive
652677.0,32 Stocks Moving In Monday's Pre-Market Session,2017-11-27 08:03:00-05:00,IDRA,neutral
652678.0,"Benzinga's Top Upgrades, Downgrades For November 9, 2017",2017-11-09 08:57:00-05:00,IDRA,positive
652679.0,"Idera Pharma Offers Translational, Clinical Data Update From Ongoing IMO-2125 Development Program: Showed 'Correlation between Proliferation and Clonal Expansion of T-Cells to Clinical Responses'",2017-11-09 07:53:00-05:00,IDRA,neutral
652680.0,"H.C. Wainwright Initiates Coverage On Idera Pharmaceuticals with Buy Rating, Announces $4.00 Price Target",2017-11-09 07:47:00-05:00,IDRA,neutral
652681.0,"Idera Pharmaceuticals Reports Q3 EPS $(0.10) vs $(0.12) Est., Sales $164K vs $130K Est.",2017-11-06 16:02:00-05:00,IDRA,neutral
652682.0,13D/A Filing Shows Baker Bros. Reporting 9.9% Stake In Idera Pharmaceuticals,2017-10-30 17:18:00-04:00,IDRA,neutral
652683.0,"Idera Pharma Director Julian Baker Buys 8,000,000 @ Avg Price: $1.50 -Form4",2017-10-30 17:14:00-04:00,IDRA,neutral
652684.0,40 Biggest Movers From Yesterday,2017-10-27 04:57:00-04:00,IDRA,neutral
652685.0,Mid-Afternoon Market Update: Buffalo Wild Wings Rises On Upbeat Earnings; Atossa Genetics Shares Plummet,2017-10-26 14:44:00-04:00,IDRA,positive
652686.0,35 Stocks Moving In Thursday's Mid-Day Session,2017-10-26 12:44:00-04:00,IDRA,neutral
652687.0,Mid-Day Market Update: Essendant Drops After Q3 Results; Achieve Life Sciences Shares Climb,2017-10-26 12:02:00-04:00,IDRA,positive
652688.0,Mid-Morning Market Update: Markets Open Higher; Twitter Beats Q3 Estimates,2017-10-26 10:04:00-04:00,IDRA,neutral
652689.0,Idera Pharmaceuticals Prices 33.33M Share Offering @$1.50/Share,2017-10-26 07:35:00-04:00,IDRA,positive
652690.0,Idera Pharma Announces $60M Offering Common Stock,2017-10-24 16:03:00-04:00,IDRA,neutral
652691.0,16 Biggest Mid-Day Gainers For Thursday,2017-10-05 12:41:00-04:00,IDRA,neutral
652692.0,20 Biggest Mid-Day Gainers For Monday,2017-09-11 12:29:00-04:00,IDRA,neutral
652693.0,18 Stocks Moving In Monday's Pre-Market Session,2017-09-11 08:27:00-04:00,IDRA,neutral
652694.0,Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy at ESMO 2017,2017-09-10 17:43:00-04:00,IDRA,positive
652695.0,Idera Pharma Offers Pre-Clinical Data From IMO-2125 In Combo With Ipilimumab: Shows Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory,2017-09-08 07:31:00-04:00,IDRA,neutral
652696.0,Idera Pharmaceuticals Reports Q2 EPS $(0.14) vs $(0.11) Est.,2017-08-07 17:13:00-04:00,IDRA,neutral
652697.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-07-18 08:08:00-04:00,IDRA,neutral
652698.0,"Trovagene Shares Volatile After Hours, Indicated Up ~4%; Likely Trading In Sympathy With Idera, Up 14% On FDA Orphan Drug News",2017-06-22 16:51:00-04:00,IDRA,positive
652699.0,Idera Pharma Reports FDA Orphan Drug Designation For IMO-2125 For Treatment Of Melanoma,2017-06-22 16:30:00-04:00,IDRA,neutral
652700.0,"With More Than 100% Upside Seen In Idera Pharma Shares, Baird Initiates At Outperform",2017-04-25 16:08:00-04:00,IDRA,positive
652701.0,22 Stocks Moving In Tuesday's Pre-Market Session,2017-04-25 08:21:00-04:00,IDRA,neutral
652702.0,"Baird Initiates Coverage On Idera Pharmaceuticals with Outperform Rating, Announces $5.00 Price Target",2017-04-24 17:00:00-04:00,IDRA,neutral
652703.0,The Market In 5 Minutes,2017-04-21 09:26:00-04:00,IDRA,neutral
652704.0,Exclusive: Idera CEO Discusses The Potential For His Company's Lead Drug Candidate,2017-04-20 14:15:00-04:00,IDRA,positive
652705.0,"Idera Pharma CEO Tells Benzinga Co. Also Dedicating Time And Energy To Secure Additional Partners For Its Third-Generation Antisense (3GA) Technology; Reiterates 'Only Two Kinds Of Deals: Done And Not Done,' Says Can Only Promise Co. Is Actively Looking",2017-04-20 14:12:00-04:00,IDRA,positive
652706.0,"Idera Pharma CEO Vin Milano In Interview With Benzinga Says Co. Is Actively Talking To Potential Partners For Licensing Of A Clinical Asset It's No Longer Pursuing, No Certainty A Deal Will Occur",2017-04-20 14:12:00-04:00,IDRA,positive
652707.0,Idera Pharmaceuticals Announces Founder Dr. Sudhir Agrawal Set To Retire,2017-04-18 16:02:00-04:00,IDRA,neutral
652708.0,20 Stocks Moving In Tuesday's Pre-Market Session,2017-04-11 09:27:00-04:00,IDRA,neutral
652709.0,"UPDATE: Idera Pharmaceuticals Reports All Objectives Successfully Met In Phase 1 Portion Of Ipilimumab Combo Trial, Co. Has Begun Registration Path Discussions With Regulators",2017-04-11 08:30:00-04:00,IDRA,positive
652710.0,Idera Pharmaceuticals Up 11.82% Premarket As Company Announces They Began Phase 2 Enrollment For Intratumoral IMO-2125 In Combination With Ipilimumab,2017-04-11 08:27:00-04:00,IDRA,neutral
652711.0,Mid-Morning Market Update: Markets Open Higher; Walgreens Sales Miss Views,2017-04-05 10:02:00-04:00,IDRA,negative
652712.0,"Myriad Genetics Says Pivotal Results From 2  Studies On myPath Melanoma Test, Says Company Will Seek Reimbursement From Both Medicare and Private Payers",2017-04-05 07:07:00-04:00,IDRA,neutral
652713.0,Idera Pharmaceuticals Says IMO-2125 Shows Mechanism Of Action Correlated With Previously Reported Clinical Results,2017-04-05 07:04:00-04:00,IDRA,neutral
652714.0,"Idera Pharma Reports Presentation of Clinical Translational, Pre-Clinical Data from IMO-2125: 'Data of Immune Parameters Generated Demonstrate IMO-2125 Mechanism of Action Correlated with Previously Reported Clinical Results'",2017-04-05 07:01:00-04:00,IDRA,positive
652715.0,Mid-Afternoon Market Update: Sears Drops After Warning Of Ability To Continue As A Going Concern; Idera Pharma Shares Surge,2017-03-22 14:51:00-04:00,IDRA,positive
652716.0,15 Biggest Mid-Day Gainers For Wednesday,2017-03-22 12:40:00-04:00,IDRA,neutral
652717.0,Mid-Day Market Update: Duluth Surges On Earnings Beat; Diana Containerships Shares Plummet,2017-03-22 12:20:00-04:00,IDRA,positive
652718.0,"Benzinga's Top Upgrades, Downgrades For March 22, 2017",2017-03-22 09:31:00-04:00,IDRA,positive
652719.0,"Idera Pharma Shares Could Be A Four-Bagger, JMP Says",2017-03-22 09:08:00-04:00,IDRA,positive
652720.0,"JMP Securities Initiates Coverage On Idera Pharmaceuticals at Market Outperform, Announces $8.00 Price Target",2017-03-22 07:37:00-04:00,IDRA,positive
652721.0,"Idera Reports EPS $0.01 vs $(0.11) Est., Sales $15.281M vs May Not Compare To $150K Est.",2017-03-15 16:35:00-04:00,IDRA,neutral
652722.0,Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients,2017-02-24 11:35:00-05:00,IDRA,neutral
652723.0,10 Stocks That Plummeted The Past Three Days On Increasing Volume,2016-12-05 06:57:00-05:00,IDRA,neutral
652724.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-28 08:24:00-05:00,IDRA,neutral
652725.0,Idera Pharmaceuticals +20% Premarket @$2.20 After Announcing Exclusive License Agreement with Vivelix Pharmaceuticals for Worldwide Rights to IMO-920,2016-11-28 07:40:00-05:00,IDRA,positive
652726.0,"Idera Pharmaceuticals, Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IMO-9200; Idera To Receive Upfront Fee Of $15M And Eligible For Future Payments Up To $140M",2016-11-28 07:01:00-05:00,IDRA,positive
652727.0,Idera Pharmaceuticals Reports Q3 EPS (0.10) vs. Prior Year Quarter $(0.10),2016-10-28 07:31:00-04:00,IDRA,neutral
652728.0,UPDATE: Baker Bros Increases Stake In Idera From 5.6% To 7.2% Stake,2016-10-11 17:22:00-04:00,IDRA,neutral
652729.0,Baker Bros Reports 7.2% Stake In Idera Pharmaceuticals,2016-10-11 17:20:00-04:00,IDRA,neutral
652730.0,18 Biggest Mid-Day Losers For Friday,2016-10-07 13:16:00-04:00,IDRA,negative
652731.0,Idera Pharmaceuticals Prices 25M Share Offering At $2/Share,2016-10-07 09:09:00-04:00,IDRA,positive
652732.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-07 08:29:00-04:00,IDRA,neutral
652733.0,Mid-Afternoon Market Update: Crude Oil Up 1.5%; Alnylam Pharma Shares Tumble On Revusiran Termination,2016-10-06 14:55:00-04:00,IDRA,negative
652734.0,Three Biotech Companies With Large Upside Potential,2016-10-06 13:25:00-04:00,IDRA,neutral
652735.0,12 Biggest Mid-Day Losers For Thursday,2016-10-06 13:19:00-04:00,IDRA,negative
652736.0,18 Stocks Moving In Thursday's Pre-Market Session,2016-10-06 08:43:00-04:00,IDRA,neutral
652737.0,Idera Pharma To Offer $50M Shares Common Stock,2016-10-05 16:01:00-04:00,IDRA,positive
652738.0,Indera Pharma Reports Data From Phase 1 Trial,2016-09-26 07:04:00-04:00,IDRA,neutral
652739.0,Mid-Day Market Update: Crude Oil Up 2.75%; Mast Therapeutics Shares Drop After Sickle Cell Drug Phase 3 Trial Fail,2016-09-21 12:16:00-04:00,IDRA,negative
652740.0,Mid-Day Market Update: Tobira Therapeutics Jumps Following Allergan Buyout; HNI Shares Slide,2016-09-20 12:16:00-04:00,IDRA,positive
652741.0,"Idera Reports Q2 EPS $(0.11) vs. Est. $(0.11), Rev. $301K vs. Est. $140K",2016-08-02 07:07:00-04:00,IDRA,neutral
652742.0,"Idera Shares Up ~$0.20 Over Last Few Mins, Up ~19% for Session",2016-06-16 11:03:00-04:00,IDRA,positive
652743.0,"Chairman Geraghty Buys 10,000 Shares of Idera Pharmaceuticals @$1.34/Share -Form 4",2016-05-16 06:57:00-04:00,IDRA,positive
652744.0,"VP Casey Buys 34,450 Shares of Idera Pharmaceuticals @$1.44/Share -Form 4",2016-05-13 09:02:00-04:00,IDRA,positive
652745.0,"Idera Pharma Reports Inline Q1 EPS $(0.11), Company is on Track to Deliver Data from 4 Clinical Trials over Next 6 to 18 Months",2016-05-09 16:01:00-04:00,IDRA,neutral
652746.0,"Idera Pharma Offers Preclinical Data Showing Enhanced Systemic Anti-Tumor Activity from Combo Treatment with Intra-tumoral IMO-2125, IDO-1 Inhibitor at AACR",2016-04-19 07:34:00-04:00,IDRA,negative
652747.0,Idera Pharmaceuticals Reports Q4 EPS $(0.10) vs. Est. $(0.11),2016-03-10 07:31:00-05:00,IDRA,neutral
652748.0,Idera Pharma Q4 EPS ($0.10) vs ($0.11) est,2016-03-10 06:42:00-05:00,IDRA,neutral
652749.0,"Julian Baker Acquires 21,246 Shares of Idera Pharmaceuticals @$3.00/Share -Form 4",2016-01-06 18:31:00-05:00,IDRA,positive
652750.0,"Wedbush Initiates Coverage on Idera Pharmaceuticals at Outperform, Announces $6.00 PT",2016-01-05 16:37:00-05:00,IDRA,neutral
652751.0,"Idera Pharma Reports Initiation of Phase 1, 2 Trial of Intra-Tumoral IMO-2125 in Combo with Ipilimumab",2015-12-14 08:08:00-05:00,IDRA,neutral
652752.0,"Shares of Idera Pharmaceuticals Up ~5.5%, Hearing Piper Jaffray Positive Comments On IMO-8400 Data From Released On Friday 12/05 After Hours",2015-12-07 10:21:00-05:00,IDRA,positive
652753.0,Idera Pharmaceuticals Reports Positive Data From Ongoing Phase 1/2 Clinical Trial of IMO-8400 at #ASH2015,2015-12-06 08:39:00-05:00,IDRA,positive
652754.0,Option Alert: $IDRA Dec $4 Call; 600 Contracts @$0.28; Ref $3.59,2015-11-27 11:46:00-05:00,IDRA,positive
652755.0,Idera to Collaborate With GSK to Identify 3rd Generation Antisense Molecules for Treatment of Renal Disease,2015-11-23 08:01:00-05:00,IDRA,neutral
652756.0,Idera Names Joanna Horobin as Chief Medical Officer,2015-11-18 08:30:00-05:00,IDRA,neutral
652757.0,Idera Pharma Reports Commencement of Phase 2 Trial of IMO-8400,2015-11-09 08:11:00-05:00,IDRA,neutral
652758.0,Idera Pharmaceuticals Reports Starting of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis,2015-11-09 08:04:00-05:00,IDRA,neutral
652759.0,"Andy Biotech Tweets ASH Conference Abstract Links For Akari Therapeutics, Idera Pharma, Pieris Pharma",2015-11-05 09:29:00-05:00,IDRA,neutral
652760.0,Andy Biotech Tweets: #ASH15 Abstracts. Tweet Has Links To Each Biotech Company's Abstract,2015-11-05 09:09:00-05:00,IDRA,neutral
652761.0,Option Alert: $IDRA Dec $3 Call Sweep; 1244 Contracts @Ask @$0.80; Now $2.92,2015-10-07 13:31:00-04:00,IDRA,positive
652762.0,Hearing Idera Plans to Purchase Embarcadero,2015-10-07 13:00:00-04:00,IDRA,neutral
652763.0,Mid-Afternoon Market Update: Cracker Barrel Drops Following Q4 Results; Intra-Cellular Therapies Shares Jump,2015-09-16 14:41:00-04:00,IDRA,positive
652764.0,Idera Pharma Reports Presentation of New Intratumoral IMO-2125 Preclinical Data at CRI-CIMT-EATI-AACR Conference,2015-09-16 09:04:00-04:00,IDRA,neutral
652765.0,Mid-Morning Market Update: Markets Open Lower; Carlyle Group To Acquire Blyth For $6/Share,2015-08-31 10:22:00-04:00,IDRA,negative
652766.0,"Idera Pharma Reports Q2 Loss of $0.11/Share, Inline, Alliance Sales $5K vs $10K Est.",2015-08-06 07:31:00-04:00,IDRA,negative
652767.0,Idera Pharmaceuticals Announces Appointment of Mark J. Casey as General Counsel and Secretary of the Board of Directors,2015-06-29 08:32:00-04:00,IDRA,neutral
652768.0,Option Alert: Idera Jul $4 Call; 1010 Contracts Traded vs 333 OI; Now $3.56,2015-06-16 15:32:00-04:00,IDRA,positive
652769.0,Mid-Afternoon Market Update: Standard Pacific Rises On Ryland Merger Deal; Micron Shares Slip,2015-06-15 15:58:00-04:00,IDRA,positive
652770.0,Mid-Day Market Update: DealerTrack Jumps On Acquisition News; AirMedia Shares Decline,2015-06-15 14:50:00-04:00,IDRA,positive
652771.0,Mid-Morning Market Update: Markets Open Lower; CVS Health To Acquire Target's Pharmacy Business for $1.9B,2015-06-15 10:47:00-04:00,IDRA,negative
652773.0,Morning Market Gainers,2015-06-15 09:43:00-04:00,IDRA,neutral
652774.0,Benzinga's Top Initiations,2015-06-15 09:10:00-04:00,IDRA,positive
652775.0,JP Morgan Initiates Idera Pharmaceuticals With Overweight,2015-06-15 09:00:00-04:00,IDRA,neutral
652776.0,Benzinga's Top #PreMarket Gainers,2015-06-15 08:15:00-04:00,IDRA,positive
652777.0,Idera Pharmaceuticals Rise 4% Premarket Following Announcement of Initiation of Buy at JP Morgan,2015-06-15 07:54:00-04:00,IDRA,positive
652778.0,JP Morgan Initiates Coverage on Idera Pharmaceuticals at Overweight,2015-06-15 07:18:00-04:00,IDRA,neutral
652779.0,Idera Pharmaceuticals Shares Spike Higher; Jul $3.5 Call Active; Now $3.60,2015-06-12 14:21:00-04:00,IDRA,positive
652780.0,Idera Pharmaceuticals Agrees To a Strategic Clinical Research Alliance With MD Anderson Cancer Center to Advance Clinical Development of Intratumoral TLR9 Agonist in Combination With Checkpoint Inhibitors,2015-06-08 08:01:00-04:00,IDRA,negative
652781.0,Idera Pharma Offers Development Update Related to IMO-9200: Pre-Clinical Data Shows Support of Candidate for Oral Therapeutic Option to Treat IBD,2015-05-18 08:34:00-04:00,IDRA,positive
652783.0,Idera Pharma Reports Q1 Loss of $0.12/Share vs Loss of $0.11/Share Est.,2015-05-11 07:30:00-04:00,IDRA,negative
652786.0,Option Alert: Idera May $3.5 Call; 1180 Contract Trade above Ask @$0.65,2015-04-09 10:55:00-04:00,IDRA,positive
652788.0,Idera Announces FDA Orphan Drug Designation for IMO-8400 for the Treatment of Diffuse Large B-Cell Lymphoma,2015-04-01 08:33:00-04:00,IDRA,neutral
652789.0,Ideara Pharmaceutical DLBCL Treatment Gains FDA Orphan Status,2015-03-31 11:08:00-04:00,IDRA,positive
652790.0,Idera Pharmaceuticals Gets FDA Orphan Designation for Treatment of Diffuse Large B-cell Lymphoma,2015-03-31 11:03:00-04:00,IDRA,neutral
652792.0,10-K from Idera Pharma Shows Q4 Loss of $0.14/Share vs Loss of $0.11/Share Est.,2015-03-12 07:42:00-04:00,IDRA,negative
652793.0,Why Cowen & Co Likes Celldex Therapeutics Following Its FDA 'Breakthrough',2015-02-24 10:43:00-05:00,IDRA,positive
652794.0,Biotech Stocks Moving Higher,2015-02-23 15:35:00-05:00,IDRA,neutral
652796.0,"IDERA Pharma Prices 20M Shares At $3.75/Share, Proceeds ~$75M",2015-02-13 08:32:00-05:00,IDRA,positive
652797.0,Morning Market Losers,2015-02-10 10:00:00-05:00,IDRA,negative
652798.0,"Morning-Market Movers Led By Aeropostale, Coca-Cola & Coupons.Com",2015-02-10 09:34:00-05:00,IDRA,neutral
652799.0,"Aeropostale, Idera Pharmaceuticals Lead Monday's After-Hours Movers",2015-02-09 18:07:00-05:00,IDRA,neutral
652800.0,Idera Pharmaceuticals Announces $75M Proposed Public Offering of Common Stock,2015-02-09 16:02:00-05:00,IDRA,neutral
652801.0,Option Alert: Idera May $5 Call; 1000 Contract Trade at Ask @$0.80; Now $4.20,2015-02-02 12:57:00-05:00,IDRA,positive
652802.0,Option Alert: Idera Mar $5 Call; 2500 Contract Trade at Ask @$0.70; Now $4.60,2015-01-21 13:54:00-05:00,IDRA,positive
652803.0,Mid-Morning Market Update: Markets Open Higher; Rite Aid Posts Rise In December Sales,2015-01-02 11:10:00-05:00,IDRA,neutral
652804.0,"Tuesday's #PreMarket Movers: Neuroderm, Microsoft, Medbox, Civeo And More",2014-12-30 09:17:00-05:00,IDRA,neutral
652805.0,UPDATE: Idera Pharmaceuticals Announces FDA Grants Orphan Drug Designation for IMO-8400,2014-12-30 08:03:00-05:00,IDRA,positive
652806.0,Idera Provides Key Updates on Clinical Development of IMO-8400 for Treatment of Waldenstrom's Macroglobulinemia,2014-12-30 08:01:00-05:00,IDRA,neutral
652807.0,UPDATE: Idera Pharmaceuticals Shares Rise 13% as Co Receives FDA Orphan Designation for Waldenstrom's Macroglobulinemia Treatment,2014-12-29 15:50:00-05:00,IDRA,positive
652808.0,"Idera Pharmaceuticals CEO Milano Buys 200,000 Shares @$4.00/Share -Form 4",2014-12-15 17:05:00-05:00,IDRA,positive
652809.0,Idera Pharmaceuticals Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual ASH Meeting,2014-12-08 17:48:00-05:00,IDRA,positive
652810.0,Mid-Morning Market Update: Markets Open Higher; Cypress To Acquire Spansion In $4 Billion Deal,2014-12-02 10:26:00-05:00,IDRA,neutral
652811.0,Idera Pharmaceuticals Names Vincent J. Milano CEO,2014-12-01 16:31:00-05:00,IDRA,neutral
652812.0,"Option Alert: Idera Pharmacueticals Nov $3 Call; 2,470 Contract Trade at Ask @$0.20; Currently $2.38",2014-11-07 15:31:00-05:00,IDRA,positive
652813.0,US Stock Futures Edge Higher; All Eyes On Jobs Data,2014-11-07 07:29:00-05:00,IDRA,neutral
652814.0,"Idera Pharmaceuticals, Inc. Reports Q3 EPS of $(0.11), Inline; Revenue of $30.0K, Up 329% YOY",2014-11-07 07:05:00-05:00,IDRA,neutral
652815.0,"Idera Pharmaceuticals, Parent Project Muscular Dystrophy to Collaborate on Advancing New Treatment Approach for DMD",2014-11-07 07:04:00-05:00,IDRA,neutral
652816.0,Idera Pharmaceuticals And Parent Project Muscular Dystrophy Announce Collaboration ,2014-11-07 07:04:00-05:00,IDRA,neutral
652817.0," Heartland Advisors eports 17.0% Passive Stake In Lincoln Educational Services as of October 31, 2014 ",2014-11-03 15:15:00-05:00,IDRA,positive
652818.0,"Option Alert: Idera Pharmacueticals Nov $2.5 Call; 2,500 Contract Trade at Ask @$0.35; Currently $2.50",2014-11-03 15:14:00-05:00,IDRA,positive
652819.0,Idera Pharma Shares Spike Higher on Note Mentioning it as Ebola Play,2014-10-14 12:09:00-04:00,IDRA,positive
652820.0,Idera Pharmaceuticals Expands Pipeline By Initiating Clinical Development Of Proprietary TLR Antagonist Candidate IMO-9200,2014-10-14 08:07:00-04:00,IDRA,negative
652821.0,"Idera Pharmaceuticals, Inc. Reports Q2 EPS of $(0.10) vs $(0.09) Est",2014-08-12 07:31:00-04:00,IDRA,neutral
652822.0,Idera Pharma Partners with The Myositis Association To Advance Development of a Novel TLR Antagonist,2014-08-07 08:13:00-04:00,IDRA,negative
652823.0,"Option Alert: Idera Pharmaceuticals Aug $3 Call; 2,220 Contracts Traded vs 473 OI; Currently $2.65",2014-07-15 15:04:00-04:00,IDRA,positive
652824.0,"Corporate Events for the Week of Jun. 2nd, 2014",2014-06-02 18:19:00-04:00,IDRA,neutral
652825.0,"Idera Pharmaceuticals Chairman Geraghty Buys 10,000 Shares @$2.65/Share -Form 4",2014-05-29 16:33:00-04:00,IDRA,positive
652826.0,Mid-Afternoon Market Update: Markets Trade In Choppy Session As Elizabeth Arden Shares Remain Down,2014-05-13 15:44:00-04:00,IDRA,positive
652827.0,Mid-Day Market Update: Rackspace Gains On Upbeat Earnings; DXP Enterprises Shares Slip,2014-05-13 12:40:00-04:00,IDRA,positive
652828.0,"Idera Pharmaceuticals, Inc. Reports Q1 EPS of $(0.12) vs $(0.08) Est",2014-05-13 07:00:00-04:00,IDRA,neutral
652829.0,"Earnings Scheduled For May 13, 2014",2014-05-13 04:32:00-04:00,IDRA,neutral
652830.0,Idera Pharma Files Shelf Offering for Up to $200M,2014-05-12 17:21:00-04:00,IDRA,neutral
652831.0,Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for IMO-8400 in Genetically Defined Forms of B-cell Lymphoma ,2014-05-08 08:32:00-04:00,IDRA,positive
652832.0,Idera Expands Management Team with Three Key Hires,2014-05-05 08:33:00-04:00,IDRA,positive
652833.0,Mid-Afternoon Market Update: Revance Therapeutics Continues to Rally as Markets Hang onto Early Strength,2014-04-22 16:01:00-04:00,IDRA,positive
652834.0,Mid-Day Market Update: Allergan Surges On Buyout Offer; Lexmark Shares Slip,2014-04-22 12:14:00-04:00,IDRA,positive
652835.0,UPDATE: Idera Pharma Says IMO-8400 Also Shows Clinical Proof of Concept in Psoriasis,2014-03-28 07:16:00-04:00,IDRA,neutral
652836.0,"Idera Pharma Announces Top-Line Data from Phase 2 Trial of IMO-8400, Says Met Primary Objective",2014-03-28 07:15:00-04:00,IDRA,neutral
652837.0,Mid-Afternoon Market Update: Markets Recover Slightly As Healthcare Stocks Continue to Show Weakness,2014-03-24 15:33:00-04:00,IDRA,negative
652838.0,Mid-Day Market Update: NASDAQ Tumbles 1.65%; Nu Skin Shares Surge After AIC China Review Update,2014-03-24 12:48:00-04:00,IDRA,positive
652839.0,Mid-Morning Market Update: Markets Mostly Lower; ReneSola Swings To Q4 Profit,2014-03-24 10:35:00-04:00,IDRA,positive
652840.0,Top Trending Tickers On StockTwits For March 13,2014-03-13 09:43:00-04:00,IDRA,positive
652841.0,Idera Pharmaceuticals Expands Pipeline into Two Orphan Autoimmune Diseases ,2014-03-13 07:36:00-04:00,IDRA,positive
652842.0,"Idera Pharmaceuticals, Inc. Reports Q4 EPS of $(0.10) vs $(0.08) Est",2014-03-13 07:08:00-04:00,IDRA,neutral
652843.0,Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally,2014-03-10 15:50:00-04:00,IDRA,neutral
652844.0,Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop,2014-03-10 12:44:00-04:00,IDRA,positive
652845.0,Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%,2014-03-10 10:35:00-04:00,IDRA,negative
652846.0,"Cowen & Company Initiates Coverage on Idera Pharmaceuticals, Inc. at Outperform",2014-03-03 08:48:00-05:00,IDRA,neutral
652847.0,Idera Pharma Prices 6.8M Share Offering at $4/Share,2014-02-05 09:10:00-05:00,IDRA,positive
652848.0,Idera Pharmaceuticals Announces Public Offering of Common Stock ,2014-02-04 16:09:00-05:00,IDRA,neutral
652849.0,Idera Pharmaceuticals Moves Higher; May be Attributed to Seeking Alpha Pro Post,2014-01-30 09:42:00-05:00,IDRA,neutral
652850.0,Longwood Capital Registers 545K Shares of Idera Pharmaceuticals,2013-12-30 15:59:00-05:00,IDRA,positive
652851.0,"Stocks to Watch for December 13, 2013",2013-12-13 13:55:00-05:00,IDRA,neutral
652852.0,"Idera Pharmaceuticals, Inc. Reports Q3 EPS of $(0.11), Inline",2013-11-14 07:39:00-05:00,IDRA,neutral
652853.0,Amended 13D Filing from Pillar Pharma on Idera Pharma Shows 19.9% Stake,2013-10-09 17:05:00-04:00,IDRA,neutral
652854.0,Morning Market Movers ,2013-10-04 10:02:00-04:00,IDRA,neutral
652855.0,13G Filing from Broadfin Capital on Idera Pharma Shows 7.68% Stake,2013-10-04 09:39:00-04:00,IDRA,neutral
652856.0,Shares of Idera Pharma Trading Higher Following Earlier 13G Filing from HealthCor Mgmt Showing 5.6% Stake,2013-10-04 08:45:00-04:00,IDRA,positive
652857.0,Morning Market Movers ,2013-10-03 10:02:00-04:00,IDRA,neutral
652858.0,Idera Pharma Closes Offering of 13.727M Shares for Gross Proceeds $27.7M,2013-09-30 16:17:00-04:00,IDRA,negative
652859.0,Idera Pharma Prices 13.7M Shares at $1.55/Share for Gross Proceeds $27.7M,2013-09-25 09:08:00-04:00,IDRA,negative
652860.0,Idera Enters Agreement with NCI to Evaluate Use of TLR Antagonists for Treatment of Genetically Defined Lymphomas ,2013-08-29 08:38:00-04:00,IDRA,positive
652861.0,Morning Market Movers ,2013-08-19 10:14:00-04:00,IDRA,neutral
652862.0,"Idera Pharmaceuticals, Inc. Reports Q2 EPS of $(0.15) vs $(0.12) Est",2013-08-15 08:01:00-04:00,IDRA,neutral
652863.0,"Idera Announces Issuance of US Patent Covering IMO-8400, Lead Candidate in Phase 2 Trial ",2013-07-18 08:04:00-04:00,IDRA,neutral
652864.0,Idera Pharma Names James Geraghty Chair,2013-07-10 09:03:00-04:00,IDRA,neutral
652865.0,Idera Pharma Reports Results of Phase 1 Trial of IMO-8400,2013-07-01 08:04:00-04:00,IDRA,neutral
652866.0,Idera Pharma to Issue Positive Phase I Trial Results on TLR Antagonist IMO-8400,2013-06-21 07:31:00-04:00,IDRA,positive
652867.0,Imminent Catalyst for Idera Pharmacueticals Should Garner Positive Investor Interest,2013-06-17 07:19:00-04:00,IDRA,positive
652868.0,Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis ,2013-06-05 08:06:00-04:00,IDRA,negative
652869.0,Idera Pharmaceuticals Announces Closing of Common Share Offering ,2013-05-07 16:18:00-04:00,IDRA,positive
652870.0,Idera Pharmaceuticals Prices 17.5M Share Offering at $0.50/Share,2013-05-02 05:59:00-04:00,IDRA,positive
652871.0,"Idera Files $15M Stock, Warrants Offering, Raised from $12.5M",2013-05-01 08:57:00-04:00,IDRA,neutral
652872.0,Idera Phase 2 of IMO-8400 Receives Clearance from Netherlands Competent Group,2013-04-01 08:18:00-04:00,IDRA,positive
652873.0,"Idera Pharma Files Mixed Securities Shelf, Max Offer $40M",2013-03-11 10:24:00-04:00,IDRA,positive
652874.0,"Idera Pharmaceuticals, Inc. Reports Q4 EPS of $(0.24), Down 4% YOY",2013-03-11 09:21:00-04:00,IDRA,neutral
652875.0,UPDATE: Piper Jaffray Initiates Idera Pharmaceuticals at Overweight on Encouraging Data  ,2013-01-03 12:49:00-05:00,IDRA,positive
652876.0,Benzinga's Top Initiations,2013-01-03 08:20:00-05:00,IDRA,positive
652877.0,"Piper Jaffray Initiates Coverage on Idera Pharmaceuticals, Inc. at Overweight, Announces $2.00 PT",2013-01-03 07:00:00-05:00,IDRA,negative
652878.0,"Benzinga's Small Cap Movers for Wednesday December 19, 2012",2012-12-19 20:25:00-05:00,IDRA,neutral
652879.0,Idera Pharmaceuticals Announces Positive Results in Phase 2 Trial of IMO-3100,2012-12-19 07:03:00-05:00,IDRA,positive
652880.0,Idera Pharmaceuticals Reports Q3 EPS $-0.17 vs $-0.11 Est,2012-11-12 08:33:00-05:00,IDRA,neutral
652881.0,Idera Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2 Trial of IMO-3100 in Patients with Psoriasis   ,2012-10-15 08:14:00-04:00,IDRA,neutral
652882.0,Idera Pharmaceuticals Reports Q2 EPS $-0.15,2012-08-09 07:33:00-04:00,IDRA,neutral
652883.0,"Idera Pharmaceuticals Reports Preclinical Mechanism of Action Data on IMO-8400, a Novel TLR Inhibitor for Autoimmune Diseases   ",2012-06-21 08:31:00-04:00,IDRA,positive
652884.0,Idera Pharmaceuticals Receives Nasdaq Listing Notice   ,2012-06-12 16:15:00-04:00,IDRA,neutral
652885.0,Idera Pharmaceuticals Announces Top-line Results from a Phase 2 Clinical Trial of IMO-2055; Did Not Meet Primary Endpoints,2012-05-03 06:36:00-04:00,IDRA,neutral
652886.0,Idera Pharmaceuticals Announces Initiation of Treatment in Phase 2 Clinical Trial of IMO-3100 for Psoriasis   ,2012-04-17 08:15:00-04:00,IDRA,neutral
652887.0,Idera Pharmaceuticals Announces Favorable Data from Phase 1b Study of IMO-2055 in Combination with Tarceva and Avastin,2012-01-20 08:00:00-05:00,IDRA,positive
652888.0,Idera Pharmaceuticals Announces Selection of Toll-like Receptor Agonist Candidates for Evaluation as Vaccine Adjuvants by Merck   ,2012-01-09 07:05:00-05:00,IDRA,neutral
652889.0,"Idera Pharmaceuticals Presents Data in Preclinical Models of Lymphoma on IMO-4200, a Dual Agonist of TLRs 7 and 8",2011-12-13 16:15:00-05:00,IDRA,neutral
652890.0,Idera Pharmaceuticals Announces FDA Authorization to Proceed with a Phase 2 Clinical Trial of IMO-3100 in Patients with Psoriasis  ,2011-12-01 08:45:00-05:00,IDRA,neutral
652891.0,Idera Pharmaceuticals Announces FDA Authorization to Proceed with a Phase 2 Clinical Trial of IMO-3100,2011-12-01 08:33:00-05:00,IDRA,neutral
652892.0,Idera Pharmaceuticals Regains Global Rights to IMO-2055 in Oncology from Merck KGaA,2011-11-30 08:33:00-05:00,IDRA,neutral
652893.0,Idera Pharmaceuticals Presents Preclinical Data on its Gene-silencing Oligonucleotides (GSOs) at EuroTIDES 2011 Conference   ,2011-11-15 08:02:00-05:00,IDRA,neutral
652894.0,Rodman & Renshaw Reiterate Market Rating And Price Target On Idera Pharmaceuticals,2011-07-22 11:35:00-04:00,IDRA,neutral
652895.0,Idera Pharmaceuticals to Resume Trading at 5:30 p.m.,2011-07-20 17:07:00-04:00,IDRA,neutral
652896.0,PREVIEW: Idera Pharmaceuticals to Resume Trading at 5:30 p.m.,2011-07-20 17:04:00-04:00,IDRA,neutral
652897.0,Idera Reports Clinical Hold on Proposed Phase 2 Clinical Trial of IMO-3100 ,2011-07-20 17:00:00-04:00,IDRA,neutral
652898.0,Idera Pharmaceuticals Halted Pending News,2011-07-20 16:56:00-04:00,IDRA,neutral
652899.0,"Rodman & Renshaw Reiterates Idera Pharmaceuticals Market Outperform, Lowers PT",2011-07-14 16:57:00-04:00,IDRA,negative
652900.0,Idera Pharmaceuticals Resumes Trading,2011-07-07 08:15:00-04:00,IDRA,neutral
652901.0,PREVIEW: APAC Customer Services and Idera Pharmaceuticals to Resume Trading at 8:15 am,2011-07-07 08:13:00-04:00,IDRA,neutral
652902.0,Idera Pharmaceuticals Provides Update on IMO-2055 Clinical Development Program   ,2011-07-07 07:48:00-04:00,IDRA,neutral
652903.0,Idera Pharma Presents Mechanism Of Action Data Of Imo-3100 In Preclinical Model Of Arthritis; Showed Significant Reduction In Arthritis Symptoms,2011-06-23 14:04:00-04:00,IDRA,positive
652904.0,Idera Pharmaceuticals Publishes Data Demonstrating Novel Gene-silencing Oligonucleotide Technology   ,2011-04-18 07:23:00-04:00,IDRA,positive
652905.0,Idera Pharmaceuticals Announces IMO-2125 Data Presentation at the 46th Annual Meeting of the European Association for the Study of the Liver ,2011-03-08 08:12:00-05:00,IDRA,neutral
652906.0,Idera Pharmaceuticals Appoints Sudhir Agrawal as Chairman of Board of Directors ,2010-10-29 08:35:00-04:00,IDRA,neutral
652907.0,Idera Pharmaceuticals Reports Second Quarter Financial Results,2010-08-05 16:01:00-04:00,IDRA,neutral
652908.0,Volume Talks Wednesday: A Bullish Biotech Breakout Option Play,2010-03-25 09:02:00-04:00,IDRA,positive
652909.0,IDRA Upgraded On Partnership Potential,2010-03-24 09:08:00-04:00,IDRA,neutral
